This Foley Executive Briefing Series program examined the common sources of litigation for life sciences companies as well as methods for mitigating exposure when these issues arise.
The program explored the potential litigation challenges that arise in light of intellectual property (IP) issues, IP ownership challenges arising out of collaborations or movements of personnel, and conflicts of interest in research, and addressed their implications for life sciences companies.
Questions that were discussed include:
- What are the key exposure areas for life sciences companies?
- What is involved in litigating these issues?
- What types of relief may be sought?
- What does litigation cost?
- Are there alternatives to litigation?
This interactive program was moderated by Foley Partners J. Mark Waxman and Thomas I. Elkind.
People
Related Insights
24 January 2025
Foley Viewpoints
Incoming Environmental Protection Agency (EPA) Personnel and Impact on Enforcement
To nobody’s surprise, it is already evident that President Trump’s second term will mark a significant shift in environmental regulation and policy from the Biden Administration.
24 February 2025
Events
Corporate Integrity Agreements: Independent Review of Organizations and the Office of the Inspector General
Foley partner Judy Waltz, chair of the firm’s Health Care Practice Group, is speaking in the Health Care Compliance Board & Compliance Committee Conference in the panel “Corporate Integrity Agreements: Independent Review of Organizations and the Office of the Inspector General.”
24 January 2025
Foley Viewpoints
Corporate Transparency Act Enforcement Remains Paused
On January 23, 2025, the U.S. Supreme Court issued a stay of the nationwide preliminary injunction issued by a federal district court in Texas in December 2024 in the Texas Top Cop Shop litigation.